Literature DB >> 23711401

Penetrating or stricturing diseases are the major determinants of time to first and repeat resection surgery in Crohn's disease.

Valerie Pittet1, Gerhard Rogler, Pierre Michetti, Nicolas Fournier, John-Paul Vader, Alain Schoepfer, Christian Mottet, Bernard Burnand, Florian Froehlich.   

Abstract

BACKGROUND: About 80% of patients with Crohn's disease (CD) require bowel resection and up to 65% will undergo a second resection within 10 years. This study reports clinical risk factors for resection surgery (RS) and repeat RS.
METHODS: Retrospective cohort study, using data from patients included in the Swiss Inflammatory Bowel Disease Cohort. Cox regression analyses were performed to estimate rates of initial and repeated RS.
RESULTS: Out of 1,138 CD cohort patients, 417 (36.6%) had already undergone RS at the time of inclusion. Kaplan-Meier curves showed that the probability of being free of RS was 65% after 10 years, 42% after 20 years, and 23% after 40 years. Perianal involvement (PA) did not modify this probability to a significant extent. The main adjusted risk factors for RS were smoking at diagnosis (hazard ratio (HR) = 1.33; p = 0.006), stricturing with vs. without PA (HR = 4.91 vs. 4.11; p < 0.001) or penetrating disease with vs. without PA (HR = 3.53 vs. 4.58; p < 0.001). The risk factor for repeat RS was penetrating disease with vs. without PA (HR = 3.17 vs. 2.24; p < 0.05).
CONCLUSION: The risk of RS was confirmed to be very high for CD in our cohort. Smoking status at diagnosis, but mostly penetrating and stricturing diseases increase the risk of RS.
Copyright © 2013 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2013        PMID: 23711401     DOI: 10.1159/000350954

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  10 in total

1.  Prostaglandin E₂ and polyenylphosphatidylcholine: stiff competition for the fibrotic complications of inflammatory bowel disease?

Authors:  Steven K Huang; Marc Peters-Golden
Journal:  Dig Dis Sci       Date:  2015-04-24       Impact factor: 3.199

2.  Association Between Plasma Level of Collagen Type III Alpha 1 Chain and Development of Strictures in Pediatric Patients With Crohn's Disease.

Authors:  Cortney R Ballengee; Ryan W Stidham; Chunyan Liu; Mi-Ok Kim; Jarod Prince; Kajari Mondal; Robert Baldassano; Marla Dubinsky; James Markowitz; Neal Leleiko; Jeffrey Hyams; Lee Denson; Subra Kugathasan
Journal:  Clin Gastroenterol Hepatol       Date:  2018-09-10       Impact factor: 11.382

3.  IL-17A Promotes Initiation and Development of Intestinal Fibrosis Through EMT.

Authors:  Hui-Jing Zhang; Yi-Ning Zhang; Huan Zhou; Lin Guan; Yue Li; Ming-Jun Sun
Journal:  Dig Dis Sci       Date:  2018-08-10       Impact factor: 3.199

Review 4.  Mechanisms, Management, and Treatment of Fibrosis in Patients With Inflammatory Bowel Diseases.

Authors:  Florian Rieder; Claudio Fiocchi; Gerhard Rogler
Journal:  Gastroenterology       Date:  2016-10-05       Impact factor: 22.682

5.  Management of Crohn's stricture: medical, endoscopic and surgical therapies.

Authors:  Mohamed Saleh Ismail; Aline Charabaty
Journal:  Frontline Gastroenterol       Date:  2022-02-16

Review 6.  Preoperative optimization of patients with inflammatory bowel disease undergoing gastrointestinal surgery: a systematic review.

Authors:  Marie Strøm Zangenberg; Nir Horesh; Uri Kopylov; Alaa El-Hussuna
Journal:  Int J Colorectal Dis       Date:  2017-10-19       Impact factor: 2.571

7.  89Zr-pro-MMP-9 F(ab')2 detects colitis induced intestinal and kidney fibrosis.

Authors:  Nicole Dmochowska; William Tieu; Marianne D Keller; Courtney A Hollis; Melissa A Campaniello; Chris Mavrangelos; Prab Takhar; Patrick A Hughes
Journal:  Sci Rep       Date:  2020-11-23       Impact factor: 4.379

Review 8.  Contribution of the Gut Microbiota to Intestinal Fibrosis in Crohn's Disease.

Authors:  Daisuke Watanabe; Nobuhiko Kamada
Journal:  Front Med (Lausanne)       Date:  2022-02-07

Review 9.  Intestinal Fibrosis in Inflammatory Bowel Disease and the Prospects of Mesenchymal Stem Cell Therapy.

Authors:  Yifei Wang; Bin Huang; Tao Jin; Dickson Kofi Wiredu Ocansey; Jiajia Jiang; Fei Mao
Journal:  Front Immunol       Date:  2022-03-18       Impact factor: 7.561

Review 10.  Dysbiotic microbiota interactions in Crohn's disease.

Authors:  Esther Caparrós; Reiner Wiest; Michael Scharl; Gerhard Rogler; Ana Gutiérrez Casbas; Bahtiyar Yilmaz; Marcin Wawrzyniak; Rubén Francés
Journal:  Gut Microbes       Date:  2021 Jan-Dec
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.